Regeneron Pharmaceuticals REGN, the biotech company, has been the subject of multiple discussions on Wall Street. Recent share price swings have prompted analysis of REGN's value, with strong recommendations for both buying and selling. It appears large firms, including Fjarde AP Fonden Fourth Swedish National Pension Fund and Allspring Global Investments Holdings LLC, have sold considerable shares, while Meritage Portfolio Management, Oregon Public Employees Retirement Fund, and Generate Investment Management Ltd have increased their portfolios.
Positive developments were reported on ongoing trials such as the pediatric severe asthma expansion, EMPOWER-Lung 3 trial, late-stage trials, and initiation of Eye Drug Trial.
Regeneron's focus on rare disease breakthroughs seems to be bearing fruit. Share value rebounded after a slump in Q2, reflecting analysts' upgrade, improving fundamentals and nearing of multiple FDA review deadlines. Factors like Dupixent's success and $83M charges in account also impact the potential investors' view on the promising future of the company.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 23 Jun 2025 07:00:00 GMT to Sat, 17 Jan 2026 09:16:23 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 5
